Quarterly Result1 Aug 2025, 12:34 pm
Hester Biosciences Q1 FY26 Results: Standalone Performance Down, Consolidated Performance Up
AI Summary
Hester Biosciences Limited has announced the unaudited financial results for Q1 FY26. The standalone performance showed a decline in the Animal Healthcare Division due to delays in government immunisation programs, while the Poultry Healthcare Division recorded a 2% growth. The consolidated performance saw a 2% growth in divisional product sales and a 131% surge in net profit. Hester Nepal and Hester Africa, subsidiaries of the company, contributed significantly to the consolidated results. The company is committed to launching new products, accelerating product diversification, and expanding its footprint in high-priority markets.
Key Highlights
- Standalone Animal Healthcare Division sales down by 33% due to delays in government immunisation programs
- Standalone Poultry Healthcare Division sales up by 2% due to robust demand for key vaccines and new products
- Consolidated divisional product sales up by 2% to INR 840.89 million
- Net profit surged by 131% driven by improved performance of subsidiaries Hester Nepal and Hester Africa
- Company committed to launching new products, accelerating product diversification, and expanding market presence